Literature DB >> 12516095

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

Annette Paschen1, Rosa María Méndez, Pilar Jimenez, Antje Sucker, Francisco Ruiz-Cabello, Mingxia Song, Federico Garrido, Dirk Schadendorf.   

Abstract

Alterations in the surface expression of HLA class I molecules have been described as a strategy of tumors to evade recognition by cytotoxic T cells. We detected complete loss of HLA class I antigen presentation for 2 tumor cell lines from 1 melanoma patient, the first originated from a regional lymph node lesion diagnosed simultaneously with the primary tumor and the second established 8 months later from a metastatic pleural effusion sample. Antigen presentation was not inducible with IFN-gamma but could be restored after transfection of tumor cells with b2m cDNA, indicating a defect in b2m expression. Analysis of the nature of this defect revealed that it originated from at least 2 mutational events affecting both copies of the b2m gene: a microdeletion of 498 bp in one b2m gene, including its entire exon 1, and a macrodeletion involving the entire copy of the second b2m gene. Microsatellite analysis pointed to the macrodeletion by demonstrating LOH for several specific markers on the long arm (q) of chromosome 15. Structural imbalance of 15q was verified by FISH. FISH studies also indicated the coexistence of a structurally abnormal variant of chromosome 15q with 2 apparently entire chromosomes 15q harboring the homozygous b2m microdeletion. Block of b2m expression in tumor cells builds a barrier to immunotherapy of cancer patients, and its early incidence should be of major consideration in the development and design of immunotherapeutic strategies. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12516095     DOI: 10.1002/ijc.10906

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

Review 1.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

2.  Deciphering the genetic evolution of T-cell resistance in melanoma.

Authors:  Antje Sucker; Annette Paschen
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.

Authors:  Isabel Maleno; Natalia Aptsiauri; Teresa Cabrera; Aurelia Gallego; Annette Paschen; Miguel Angel López-Nevot; Federico Garrido
Journal:  Immunogenetics       Date:  2010-11-18       Impact factor: 2.846

4.  Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth.

Authors:  Céline A Blache; Edwin R Manuel; Teodora I Kaltcheva; Andrea N Wong; Joshua D I Ellenhorn; Bruce R Blazar; Don J Diamond
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

Review 5.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

6.  LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.

Authors:  Jacky T Yeung; Ronald L Hamilton; Koji Ohnishi; Maki Ikeura; Douglas M Potter; Marina N Nikiforova; Soldano Ferrone; Regina I Jakacki; Ian F Pollack; Hideho Okada
Journal:  Clin Cancer Res       Date:  2013-02-11       Impact factor: 12.531

7.  Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I-deficient breast cancer cells.

Authors:  Ming-Zhen Zhao; Yu Sun; Xiao-Feng Jiang; Li Liu; Li Liu; Li-Xin Sun
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

8.  Genetic evolution of T-cell resistance in the course of melanoma progression.

Authors:  Antje Sucker; Fang Zhao; Birgit Real; Christina Heeke; Nicola Bielefeld; Stefan Maβen; Susanne Horn; Iris Moll; Raffaela Maltaner; Peter A Horn; Bastian Schilling; Francesco Sabbatino; Volker Lennerz; Matthias Kloor; Soldano Ferrone; Dirk Schadendorf; Christine S Falk; Klaus Griewank; Annette Paschen
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

Review 9.  MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Authors:  Steven X Cho; Saptha Vijayan; Ji-Seung Yoo; Toshiyuki Watanabe; Ryota Ouda; Ning An; Koichi S Kobayashi
Journal:  Immunology       Date:  2020-08-03       Impact factor: 7.397

10.  Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.

Authors:  Teresa Rodríguez; Rosa Méndez; Ana Del Campo; Pilar Jiménez; Natalia Aptsiauri; Federico Garrido; Francisco Ruiz-Cabello
Journal:  BMC Cancer       Date:  2007-02-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.